Research
Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
BMJ 2018; 360 doi: https://doi.org/10.1136/bmj.k793 (Published 14 March 2018) Cite this as: BMJ 2018;360:k793
Data supplement
Web Extra
- Data Supplement - Appendix: Supplementary materials
Related articles
- Research Methods & Reporting Published: 18 October 2011; BMJ 343 doi:10.1136/bmj.d5928
- Research Published: 21 November 2014; BMJ 349 doi:10.1136/bmj.g6501
- Research Published: 10 September 2018; BMJ 362 doi:10.1136/bmj.k3529
See more
- Introductory AddressProv Med Surg J October 03, 1840, s1-1 (1) 1-4; DOI: https://doi.org/10.1136/bmj.s1-1.1.1
- Report of the Meeting of the Eastern Branch of the Provincial Association at Bury St. Edmond'sProv Med Surg J October 03, 1840, s1-1 (1) 10-13; DOI: https://doi.org/10.1136/bmj.s1-1.1.10
- Mr. Warburton's Bill for the Regulation of the Medical ProfessionProv Med Surg J October 03, 1840, s1-1 (1) 13-15; DOI: https://doi.org/10.1136/bmj.s1-1.1.13
- An Atlas of Plates, illustrative of the Principles and Practice of Obstetric Medicine and Surgery, with descriptive LetterpressProv Med Surg J October 03, 1840, s1-1 (1) 4; DOI: https://doi.org/10.1136/bmj.s1-1.1.4
- A Practical Treatise on the Diseases peculiar to Women, illustrated by Cases, &cProv Med Surg J October 03, 1840, s1-1 (1) 4-5; DOI: https://doi.org/10.1136/bmj.s1-1.1.4-a
Cited by...
- Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma
- Impaired in vitro Interferon-{gamma} production in patients with visceral leishmaniasis is improved by inhibition of PD1/PDL-1 ligation
- CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study
- CX-072 (pacmilimab), a Probody(R) PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study
- Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem
- Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA
- Predictive Impact of Prognostic Nutritional Index on Pembrolizumab for Metastatic Urothelial Carcinoma Resistant to Platinum-based Chemotherapy
- Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
- Toxicities of PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis
- Preclinical platform for long-term evaluation of immuno-oncology drugs using hCD34+ humanized mouse model
- HDAC6 Plays a Noncanonical Role in the Regulation of Antitumor Immune Responses, Dissemination, and Invasiveness of Breast Cancer
- Rare case of life-threatening thrombocytopenia occurring after radiotherapy in a patient treated with immune checkpoint inhibitor
- Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors
- Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology
- CD200 Checkpoint Reversal: A Novel Approach to Immunotherapy
- Chronic intestinal pseudo-obstruction in a patient with metastatic gastro-oesophageal junction cancer receiving treatment with pembrolizumab
- CD200 immune checkpoint reversal at the site of tumor vaccine inoculation: A novel approach to glioblastoma immunotherapy
- Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity
- Cascade of immunologic adverse events related to pembrolizumab treatment
- Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics
- Immunotherapy causing pneumonitis in a patient with non-small cell lung cancer (NSCLC)
- Resolution of Pembrolizumab-Associated Steroid-Refractory Lichenoid Dermatitis with Cyclosporine
- CiTE antibody for AML
- Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis